CoChat

Functions and therapeutic targets of Siglec-mediated infections, inflammations and cancers

Lin, Chia-Hsueh, Yeh, Ying-Chun, Yang, Kuender D. · 2021 · Journal of the Formosan Medical Association
Cited by 57

The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.jfma.2019.10.019

Cites

11 of 11 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 160

  1. Crocker, 2007, Siglecs and their roles in the immune system, Nat Rev Immunol, 7, 255, 10.1038/nri2056 · DOI · Paper page
  2. von Gunten, 2008, Basic and clinical immunology of siglecs, Ann N Y Acad Sci, 1143, 61, 10.1196/annals.1443.011 · DOI · Paper page
  3. Chang, 2014, The interplay between Siglecs and sialylated pathogens, Glycobiology, 24, 818, 10.1093/glycob/cwu067 · DOI · Paper page
  4. O'Neill, 2013, Sialoadhesin—a macrophage-restricted marker of immunoregulation and inflammation, Immunology, 138, 198, 10.1111/imm.12042 · DOI · Paper page
  5. Bornhöfft, 2018, Siglecs: a journey through the evolution of sialic acid-binding immunoglobulin-type lectins, Dev Comp Immunol, 86, 219, 10.1016/j.dci.2018.05.008 · DOI
  6. Varki, 2001, Loss of N-glycolylneuraminic acid in humans: mechanisms, consequences, and implications for hominid evolution, Am J Phys Anthropol, Suppl 33, 54, 10.1002/ajpa.10018 · DOI · Paper page
  7. Varki, 2010, Uniquely human evolution of sialic acid genetics and biology, Proc Natl Acad Sci USA, 107, 8939, 10.1073/pnas.0914634107 · DOI · Paper page
  8. Crocker, 2008, Siglecs as positive and negative regulators of the immune system, Biochem Soc Trans, 36, 1467, 10.1042/BST0361467 · DOI · Paper page
  9. Blasius, 2006, Siglec-H is an IPC-specific receptor that modulates type I IFN secretion through DAP12, Blood, 107, 2474, 10.1182/blood-2005-09-3746 · DOI · Paper page
  10. Takamiya, 2013, The interaction between Siglec-15 and tumor-associated sialyl-Tn antigen enhances TGF-β secretion from monocytes/macrophages through the DAP12-Syk pathway, Glycobiology, 23, 178, 10.1093/glycob/cws139 · DOI · Paper page
  11. Angata, 2014, Associations of genetic polymorphisms of Siglecs with human diseases, Glycobiology, 24, 785, 10.1093/glycob/cwu043 · DOI · Paper page
  12. Walter, 2008, ITIM-dependent endocytosis of CD33-related Siglecs: role of intracellular domain, tyrosine phosphorylation, and the tyrosine phosphatases, Shp1 and Shp2, J Leukoc Biol, 83, 200, 10.1189/jlb.0607388 · DOI · Paper page
  13. Jellusova, 2012, Regulation of B cell functions by the sialic acid-binding receptors siglec-G and CD22, Front Immunol, 2, 96, 10.3389/fimmu.2011.00096 · DOI · Paper page
  14. Simmons, 1988, Isolation of a cDNA encoding CD33, a differentiation antigen of myeloid progenitor cells, J Immunol, 141, 2797, 10.4049/jimmunol.141.8.2797 · DOI
  15. Falco, 1999, Identification and molecular cloning of p75/AIRM1, a novel member of the sialoadhesin family that functions as an inhibitory receptor in human natural killer cells, J Exp Med, 190, 793, 10.1084/jem.190.6.793 · DOI · Paper page
  16. Nicoll, 1999, Identification and characterization of a novel siglec, siglec-7, expressed by human natural killer cells and monocytes, J Biol Chem, 274, 34089, 10.1074/jbc.274.48.34089 · DOI · Paper page
  17. von Gunten, 2005, Siglec-9 transduces apoptotic and nonapoptotic death signals into neutrophils depending on the proinflammatory cytokine environment, Blood, 106, 1423, 10.1182/blood-2004-10-4112 · DOI · Paper page
  18. Crocker, 2001, Siglecs in the immune system, Immunology, 103, 137, 10.1046/j.0019-2805.2001.01241.x · DOI · Paper page
  19. Angata, 2006, Discovery of Siglec-14, a novel sialic acid receptor undergoing concerted evolution with Siglec-5 in primates, FASEB J, 20, 1964, 10.1096/fj.06-5800com · DOI · Paper page
  20. Angata, 2007, Siglec-15: an immune system Siglec conserved throughout vertebrate evolution, Glycobiology, 17, 838, 10.1093/glycob/cwm049 · DOI · Paper page
  21. Yamaji, 2005, Characterization of inhibitory signaling motifs of the natural killer cell receptor Siglec-7: attenuated recruitment of phosphatases by the receptor is attributed to two amino acids in the motifs, Glycobiology, 15, 667, 10.1093/glycob/cwi048 · DOI
  22. Angata, 2018, Possible influences of endogenous and exogenous ligands on the evolution of human Siglecs, Front Immunol, 9, 2885, 10.3389/fimmu.2018.02885 · DOI
  23. Dankwa, 2016, Ancient human sialic acid variant restricts an emerging zoonotic malaria parasite, Nat Commun, 7, 11187, 10.1038/ncomms11187 · DOI · Paper page
  24. Rumer, 2012, Siglec-6 is expressed in gestational trophoblastic disease and affects proliferation, apoptosis and invasion, Endocr Relat Cancer, 19, 827, 10.1530/ERC-11-0379 · doi:10.1530/erc-11-0379
  25. Sammar, 2017, Expression of CD24 and Siglec-10 in first trimester placenta: implications for immune tolerance at the fetal-maternal interface, Histochem Cell Biol, 147, 565, 10.1007/s00418-016-1531-7 · DOI
  26. Wang, 2011, Expression of Siglec-11 by human and chimpanzee ovarian stromal cells, with uniquely human ligands: implications for human ovarian physiology and pathology, Glycobiology, 21, 1038, 10.1093/glycob/cwr039 · DOI
  27. Wang, 2012, Evolution of siglec-11 and siglec-16 genes in hominins, Mol Biol Evol, 29, 2073, 10.1093/molbev/mss077 · DOI · Paper page
  28. Wang, 2012, Specific inactivation of two immunomodulatory SIGLEC genes during human evolution, Proc Natl Acad Sci USA, 109, 9935, 10.1073/pnas.1119459109 · DOI · Paper page
  29. Orr, 2007, CD33 responses are blocked by SOCS3 through accelerated proteasomal-mediated turnover, Blood, 109, 1061, 10.1182/blood-2006-05-023556 · DOI
  30. Lübbers, 2018, Modulation of immune tolerance via Siglec-sialic acid interactions, Front Immunol, 9, 2807, 10.3389/fimmu.2018.02807 · DOI · Paper page
  31. Varchetta, 2012, Engagement of Siglec-7 receptor induces a pro-inflammatory response selectively in monocytes, PLoS One, 7, 10.1371/journal.pone.0045821 · DOI
  32. Cao, 2008, SIGLEC16 encodes a DAP12-associated receptor expressed in macrophages that evolved from its inhibitory counterpart SIGLEC11 and has functional and non-functional alleles in humans, Eur J Immunol, 38, 2303, 10.1002/eji.200738078 · DOI · Paper page
  33. Hitomi, 2007, Association of CD22 gene polymorphism with susceptibility to limited cutaneous systemic sclerosis, Tissue Antigens, 69, 242, 10.1111/j.1399-0039.2007.00801.x · DOI
  34. Jitoku, 2011, Association study of Nogo-related genes with schizophrenia in a Japanese case-control sample, Am J Med Genet B Neuropsychiatr Genet, 156B, 581, 10.1002/ajmg.b.31199 · DOI
  35. Gao, 2010, Polymorphisms in the sialic acid-binding immunoglobulin-like lectin-8 (Siglec-8) gene are associated with susceptibility to asthma, Eur J Hum Genet, 18, 713, 10.1038/ejhg.2009.239 · DOI
  36. Ishii, 2017, Influence of SIGLEC9 polymorphisms on COPD phenotypes including exacerbation frequency, Respirology, 22, 684, 10.1111/resp.12952 · DOI
  37. Ali, 2014, Siglec-5 and Siglec-14 are polymorphic paired receptors that modulate neutrophil and amnion signaling responses to group B Streptococcus, J Exp Med, 211, 1231, 10.1084/jem.20131853 · DOI · Paper page
  38. Angata, 2014, Association of serum interleukin-27 with the exacerbation of chronic obstructive pulmonary disease, Physiol Rep, 2, 10.14814/phy2.12069 · DOI
  39. Lee, 2010, Hypermucoviscosity associated with Klebsiella pneumoniae-mediated invasive syndrome: a prospective cross-sectional study in Taiwan, Int J Infect Dis, 14, e688, 10.1016/j.ijid.2010.01.007 · DOI
  40. Lee, 2014, Aspirin enhances opsonophagocytosis and is associated to a lower risk for Klebsiella pneumoniae invasive syndrome, BMC Infect Dis, 14, 47, 10.1186/1471-2334-14-47 · DOI
  41. Lee, 2014, Sialic acid involved in hypermucoviscosity phenotype of Klebsiella pneumoniae and associated with resistance to neutrophil phagocytosis, Virulence, 5, 673, 10.4161/viru.32076 · DOI
  42. Chang, 2014, Role of macrophage sialoadhesin in host defense against the sialylated pathogen group B Streptococcus, J Mol Med, 92, 951, 10.1007/s00109-014-1157-y · DOI
  43. Liu, 2017, Sialic acids in the immune response during sepsis, Front Immunol, 8, 1601, 10.3389/fimmu.2017.01601 · DOI
  44. Jones, 2003, Recognition of sialylated meningococcal lipopolysaccharide by siglecs expressed on myeloid cells leads to enhanced bacterial uptake, Mol Microbiol, 49, 1213, 10.1046/j.1365-2958.2003.03634.x · DOI · Paper page
  45. Heikema, 2010, Characterization of the specific interaction between sialoadhesin and sialylated Campylobacter jejuni lipooligosaccharides, Infect Immun, 78, 3237, 10.1128/IAI.01273-09 · DOI · Paper page
  46. Schwarz, 2017, Paired Siglec receptors generate opposite inflammatory responses to a human-specific pathogen, EMBO J, 36, 751, 10.15252/embj.201695581 · DOI
  47. Roy, 2016, Leishmania donovani utilize sialic acids for binding and phagocytosis in the macrophages through selective utilization of Siglecs and impair the innate immune arm, PLoS Negl Trop Dis, 10, 10.1371/journal.pntd.0004904 · DOI
  48. Erdmann, 2009, Sialylated ligands on pathogenic Trypanosoma cruzi interact with Siglec-E (sialic acid-binding Ig-like lectin-E), Cell Microbiol, 11, 1600, 10.1111/j.1462-5822.2009.01350.x · DOI
  49. Jacobs, 2010, Molecular interaction of Siglecs (sialic acid-binding Ig-like lectins) with sialylated ligands on Trypanosoma cruzi, Eur J Cell Biol, 89, 113, 10.1016/j.ejcb.2009.10.006 · DOI
  50. Orlandi, 1992, A malaria invasion receptor, the 175-kilodalton erythrocyte binding antigen of Plasmodium falciparum recognizes the terminal Neu5Ac(alpha 2-3)Gal− sequences of glycophorin A, J Cell Biol, 116, 901, 10.1083/jcb.116.4.901 · DOI · Paper page
  51. Air, 2014, Influenza virus-glycan interactions, Curr Opin Virol, 7, 128, 10.1016/j.coviro.2014.06.004 · DOI
  52. Ito, 1998, Molecular basis for the generation in pigs of influenza A viruses with pandemic potential, J Virol, 72, 7367, 10.1128/JVI.72.9.7367-7373.1998 · DOI · Paper page
  53. Jobe, 2016, Effect of cytokines on Siglec-1 and HIV-1 entry in monocyte-derived macrophages: the importance of HIV-1 envelope V1V2 region, J Leukoc Biol, 99, 1089, 10.1189/jlb.2A0815-361R · DOI
  54. Brunetta, 2009, The decreased expression of Siglec-7 represents an early marker of dysfunctional natural killer–cell subsets associated with high levels of HIV-1 viremia, Blood, 114, 3822, 10.1182/blood-2009-06-226332 · DOI
  55. Suenaga, 2010, Myelin-associated glycoprotein mediates membrane fusion and entry of neurotropic herpesviruses, Proc Natl Acad Sci USA, 107, 866, 10.1073/pnas.0913351107 · DOI · Paper page
  56. Suenaga, 2015, Sialic acids on Varicella-Zoster virus glycoprotein B are required for cell-cell Fusion, J Biol Chem, 290, 19833, 10.1074/jbc.M114.635508 · DOI
  57. Puttur, 2013, Absence of Siglec-H in MCMV infection elevates interferon alpha production but does not enhance viral clearance, PLoS Pathog, 9, 10.1371/journal.ppat.1003648 · DOI
  58. Yokoi, 2008, Inhibition of FceRI-dependent mediator release and calcium flux from human mast cells by Siglec-8 engagement, J Allergy Clin Immunol, 121, 499, 10.1016/j.jaci.2007.10.004 · DOI
  59. Ando, 2008, Siglec-9 enhances IL-10 production in macrophages via tyrosine-based motifs, Biochem Biophys Res Commun, 369, 878, 10.1016/j.bbrc.2008.02.111 · DOI
  60. Chen, 2014, Broad and direct interaction between TLR and Siglec families of pattern recognition receptors and its regulation by Neu1, Elife, 3, 10.7554/eLife.04066 · DOI · Paper page
  61. Bochner, 2009, Siglec-8 on human eosinophils and mast cells, and Siglec-F on murine eosinophils, are functionally related inhibitory receptors, Clin Exp Allergy, 39, 317, 10.1111/j.1365-2222.2008.03173.x · DOI · Paper page
  62. Jang, 2014, Additive anti-allergic effects of anti-interleukin-33 and anti-Siglec-F treatments in a murine model of allergic asthma, Cent Eur J Immunol, 39, 426, 10.5114/ceji.2014.47724 · doi:10.5114/ceji.2014.47724
  63. Mizrahi, 2014, Siglec-7 is an inhibitory receptor on human mast cells and basophils, J Allergy Clin Immunol, 134, 230, 10.1016/j.jaci.2014.03.031 · DOI
  64. Mahajan, 2016, Sialic acids and autoimmune disease, Immunol Rev, 269, 145, 10.1111/imr.12344 · DOI · Paper page
  65. Xiong, 2014, Increased expression of Siglec-1 on peripheral blood monocytes and its role in mononuclear cell reactivity to autoantigen in rheumatoid arthritis, Rheumatology (Oxford), 53, 250, 10.1093/rheumatology/ket342 · DOI
  66. York, 2007, A macrophage marker, siglec-1, is increased on circulating monocytes in patients with systemic sclerosis and induced by type I interferons and toll-like receptor agonists, Arthritis Rheum, 56, 1010, 10.1002/art.22382 · DOI · Paper page
  67. Wilhelm, 2016, Siglec-1-positive plasmacytoid dendritic cells (pDCs) in human peripheral blood: a semi-mature and myeloid-like subset imbalanced during protective and autoimmune responses, Clin Immunol, 163, 42, 10.1016/j.clim.2015.12.001 · DOI
  68. Madge, 2016, Structural characterisation of high affinity Siglec-2 (CD22) ligands in complex with whole Burkitt's lymphoma (BL) Daudi cells by NMR spectroscopy, Sci Rep, 6, 36012, 10.1038/srep36012 · doi:10.1038/srep36012
  69. Müller, 2014, The role of CD22 and Siglec-G in B-cell tolerance and autoimmune disease, Nat Rev Rheumatol, 10, 422, 10.1038/nrrheum.2014.54 · DOI
  70. Müller, 2015, Siglec-G deficiency leads to autoimmunity in aging C57BL/6 mice, J Immunol, 195, 51, 10.4049/jimmunol.1403139 · DOI
  71. Litschke, 2014, CD22 and Siglec-G regulate inhibition of B-cell signaling by sialic acid ligand binding and control B-cell tolerance, Glycobiology, 24, 807, 10.1093/glycob/cwu066 · DOI
  72. Karasawa, 2015, Vascular-resident CD169-positive monocytes and macrophages control neutrophil accumulation in the kidney with ischemia-reperfusion injury, J Am Soc Nephrol, 26, 896, 10.1681/ASN.2014020195 · DOI · Paper page
  73. Pepin, 2015, Soluble Siglec-5 associates to PSGL-1 and displays anti-inflammatory activity, J Am Soc Nephrol, 26, 896
  74. Fong, 2015, Immunomodulatory activity of extracellular Hsp70 mediated via paired receptors Siglec-5 and Siglec-14, EMBO J, 34, 2775, 10.15252/embj.201591407 · DOI
  75. Nguyen, 2014, Role of Siglec-7 in apoptosis in human platelets, PLoS One, 9, 10.1371/journal.pone.0106239 · DOI
  76. McMillan, 2014, Siglec-E promotes β2-integrin-dependent NADPH oxidase activation to suppress neutrophil recruitment to the lung, J Biol Chem, 289, 20370, 10.1074/jbc.M114.574624 · DOI
  77. Rashmi, 2009, Siglec-9 and SHP-1 are differentially expressed in neonatal and adult neutrophils, Pediatr Res, 66, 266, 10.1203/PDR.0b013e3181b1bc19 · DOI
  78. Jia, 2015, Expression of ligands for Siglec-8 and Siglec-9 in human airways and airway cells, J Allergy Clin Immunol, 135, 799, 10.1016/j.jaci.2015.01.004 · DOI
  79. Banda, 2012, Metabolism of vertebrate amino sugars with N-glycolyl groups: mechanisms underlying gastrointestinal incorporation of the non-human sialic acid xeno-autoantigen N-glycolylneuraminic acid, J Biol Chem, 287, 28852, 10.1074/jbc.M112.364182 · DOI · Paper page
  80. Taylor, 2010, Novel mechanism for the generation of human xeno-autoantibodies against the nonhuman sialic acid N-glycolylneuraminic acid, J Exp Med, 207, 1637, 10.1084/jem.20100575 · DOI · Paper page
  81. Samraj, 2015, A red meat-derived glycan promotes inflammation and cancer progression, Proc Natl Acad Sci USA, 112, 542, 10.1073/pnas.1417508112 · DOI · Paper page
  82. Schwarz, 2015, Siglec receptors impact mammalian lifespan by modulating oxidative stress, eLife, 7, 4
  83. Fehervari, 2015, A Siglec link to aging, Nat Immunol, 16, 598
  84. Groh, 2016, Sialoadhesin promotes neuroinflammation-related disease progression in two mouse models of CLN disease, Glia, 64, 792, 10.1002/glia.22962 · DOI · Paper page
  85. Schwarz, 2016, Human-specific derived alleles of CD33 and other genes protect against postreproductive cognitive decline, Proc Natl Acad Sci USA, 113, 74, 10.1073/pnas.1517951112 · DOI
  86. DeBellard, 1996, Myelin-associated glycoprotein inhibits axonal regeneration from a variety of neurons via interaction with a sialoglycoprotein, Mol Cell Neurosci, 7, 89, 10.1006/mcne.1996.0007 · DOI · Paper page
  87. Shen, 2011, Age-related changes in myelin morphology, electrophysiological property and myelin-associated protein expression of mouse sciatic nerves, Neurosci Lett, 502, 162, 10.1016/j.neulet.2011.07.034 · DOI
  88. Xu, 2014, Peripheral surgical wounding and age-dependent neuroinflammation in mice, PLoS One, 9
  89. Mizuno, 2016, Network analysis of a comprehensive knowledge repository reveals a dual role for ceramide in Alzheimer's disease, PLoS One, 11, 10.1371/journal.pone.0148431 · DOI
  90. Komohara, 2017, Possible functions of CD169-positive sinus macrophages in lymph nodes in anti-tumor immune responses, Cancer Sci, 108, 290, 10.1111/cas.13137 · DOI
  91. Black, 2016, The CD169 sialoadhesin molecule mediates cytotoxic T-cell responses to tumour apoptotic vesicles, Immunol Cell Biol, 94, 430, 10.1038/icb.2015.111 · DOI
  92. Li, 2015, A higher frequency of CD14+ CD169+ monocytes/macrophages in patients with colorectal cancer, PLoS One, 10
  93. Meyer, 2018, B Cell Siglecs–News on signaling and its interplay with ligand binding, Front Immunol, 9, 2820, 10.3389/fimmu.2018.02820 · DOI · Paper page
  94. Yoshida, 2017, Efficacy of an anti-CD22 antibody-monomethyl auristatin E conjugate in a preclinical xenograft model of precursor B-cell acute lymphoblastic leukemia, Leuk Lymphoma, 58, 1254, 10.1080/10428194.2016.1235273 · doi:10.1080/10428194.2016.1235273
  95. Herrmann, 2012, CD34+/CD38− stem cells in chronic myeloid leukemia express Siglec-3 (CD33) and are responsive to the CD33-targeting drug gemtuzumab/ozogamicin, Haematologica, 97, 219, 10.3324/haematol.2010.035006 · DOI · Paper page
  96. Balaian, 2006, Cytotoxic activity of gemtuzumab ozogamicin (Mylotarg) in acute myeloid leukemia correlates with the expression of protein kinase Syk, Leukemia, 20, 2093, 10.1038/sj.leu.2404437 · DOI
  97. Liu, 2012, Therapeutic potential of perineural invasion, hypoxia and desmoplasia in pancreatic cancer, Curr Pharm Des, 18, 2395, 10.2174/13816128112092395 · DOI
  98. Shao, 2016, Siglec-7 defines a highly functional natural killer cell subset and inhibits cell-mediated activities, Scand J Immunol, 84, 182, 10.1111/sji.12455 · DOI
  99. Läubli, 2014, Engagement of myelomonocytic Siglecs by tumor-associated ligands modulates the innate immune response to cancer, Proc Natl Acad Sci USA, 111, 14211, 10.1073/pnas.1409580111 · DOI · Paper page
  100. Stanczak, 2018, Self-associated molecular patterns mediate cancer immune evasion by engaging Siglecs on T cells, J Clin Invest, 128, 4912, 10.1172/JCI120612 · DOI · Paper page
  101. Mitra, 2011, SIGLEC12, a human-specific segregating (Pseudo) gene, encodes a signaling molecule expressed in prostate carcinomas, J Biol Chem, 286, 23003, 10.1074/jbc.M111.244152 · DOI
  102. O'Reilly, 2009, Siglecs as targets for therapy in immune cell mediated disease, Trends Pharmacol Sci, 30, 240, 10.1016/j.tips.2009.02.005 · DOI · Paper page
  103. Angata, 2015, Therapeutic targeting of Siglecs using antibody- and glycan-based approaches, Trends Pharmacol Sci, 36, 645, 10.1016/j.tips.2015.06.008 · DOI
  104. Kawasaki, 2013, Targeted delivery of lipid antigen to macrophages via the CD169/sialoadhesin endocytic pathway induces robust invariant natural killer T cell activation, Proc Natl Acad Sci USA, 110, 7826, 10.1073/pnas.1219888110 · DOI · Paper page
  105. De Schryver, 2017, Comparative analysis of the internalization of the macrophage receptor sialoadhesin in human and mouse primary macrophages and cell lines, Immunobiology, 222, 797, 10.1016/j.imbio.2016.11.013 · DOI
  106. Chen, 2012, Antigen delivery to macrophages using liposomal nanoparticles targeting sialoadhesin/CD169, PLoS One, 7
  107. Macauley, 2013, Antigenic liposomes displaying CD22 ligands induce antigen-specific B cell apoptosis, J Clin Invest, 123, 3074, 10.1172/JCI69187 · DOI · Paper page
  108. Chang, 2015, Extensive crosslinking of CD22 by epratuzumab triggers BCR signaling and caspase-dependent apoptosis in human lymphoma cells, MAbs, 7, 199, 10.4161/19420862.2014.979081 · DOI
  109. Bera, 2014, An improved recombinant Fab-immunotoxin targeting CD22 expressing malignancies, Leuk Res, 38, 1224, 10.1016/j.leukres.2014.06.014 · doi:10.1016/j.leukres.2014.06.014
  110. Bachanova, 2015, Phase I study of a bispecific ligand-directed toxin targeting CD22 and CD19 (DT2219) for refractory B-cell malignancies, Clin Cancer Res, 21, 1267, 10.1158/1078-0432.CCR-14-2877 · DOI
  111. 2017, Anti-CD22 CAR therapy leads to ALL remissions, Cancer Discov, 7, 120, 10.1158/2159-8290.CD-NB2017-001 · DOI
  112. Loke, 2015, Mylotarg has potent anti-leukaemic effect: a systematic review and meta-analysis of anti-CD33 antibody treatment in acute myeloid leukaemia, Ann Hematol, 94, 361, 10.1007/s00277-014-2218-6 · DOI
  113. Reusch, 2016, Characterization of CD33/CD3 tetravalent bispecific tandem diabodies (TandAbs) for the treatment of acute myeloid leukemia, Clin Cancer Res, 22, 5829, 10.1158/1078-0432.CCR-16-0350 · DOI
  114. Cartellieri, 2016, Switching CAR T cells on and off: a novel modular platform for retargeting of T cells to AML blasts, Blood Cancer J, 6, e458, 10.1038/bcj.2016.61 · DOI · Paper page
  115. Aliperta, 2017, Cryogel-supported stem cell factory for customized sustained release of bispecific antibodies for cancer immunotherapy, Sci Rep, 7, 42855, 10.1038/srep42855 · DOI
  116. Irving, 2005, Identification of neuroprotective properties of anti-MAG antibody: a novel approach for the treatment of stroke?, J Cereb Blood Flow Metab, 25, 98, 10.1038/sj.jcbfm.9600011 · DOI
  117. Schachner, 2000, Multiple functions of the myelin-associated glycoprotein MAG (siglec-4a) in formation and maintenance of myelin, Glia, 29, 154, 10.1002/(SICI)1098-1136(20000115)29:2<154::AID-GLIA9>3.0.CO;2-3 · DOI · Paper page
  118. Cramer, 2013, MAG111539 Study Investigators. Safety, pharmacokinetics, and pharmacodynamics of escalating repeat doses of GSK249320 in patients with stroke, Stroke, 44, 1337, 10.1161/STROKEAHA.111.674366 · DOI
  119. Cash, 2016, GSK249320, a monoclonal antibody against the axon outgrowth inhibition molecule myelin-associated glycoprotein, improves outcome of rodents with experimental stroke, J Neurol Exp Neurosci, 2, 28
  120. Blixt, 2003, Sialoside specificity of the Siglec family assessed using novel multivalent probes: identification of potent inhibitors of myelin associated glycoprotein, J Biol Chem, 278, 31007, 10.1074/jbc.M304331200 · DOI · Paper page
  121. Yamanaka, 2009, Deletion polymorphism of SIGLEC14 and its functional implications, Glycobiology, 19, 841, 10.1093/glycob/cwp052 · DOI
  122. Yasui, 2011, Detection of anti-Siglec-14 alloantibodies in blood components implicated in nonhaemolytic transfusion reactions, Br J Haematol, 153, 794, 10.1111/j.1365-2141.2010.08488.x · doi:10.1111/j.1365-2141.2010.08488.x
  123. Patel, 1999, OB-BP1/Siglec-6, a leptin- and sialic acid-binding protein of the immunoglobulin superfamily, J Biol Chem, 274, 22729, 10.1074/jbc.274.32.22729 · DOI · Paper page
  124. Rumer, 2013, Siglec-6 expression is increased in placentas from pregnancies complicated by preterm preeclampsia, Reprod Sci, 20, 646, 10.1177/1933719112461185 · doi:10.1177/1933719112461185
  125. Nicolr, 2003, Ganglioside GD3 expression on target cells can modulate NK cell cytotoxicity via siglec-7-dependent and -independent mechanisms, Eur J Immunol, 33, 1642, 10.1002/eji.200323693 · DOI · Paper page
  126. Kawasaki, 2014, Targeted delivery of mycobacterial antigens to human dendritic cells via Siglec-7 induces robust T cell activation, J Immunol, 193, 1560, 10.4049/jimmunol.1303278 · DOI
  127. Spence, 2015, Targeting Siglecs with a sialic acid-decorated nanoparticle abrogates inflammation, Sci Transl Med, 7, 303ra140, 10.1126/scitranslmed.aab3459 · DOI · Paper page
  128. Rubinstein, 2011, Siglec-F inhibition reduces esophageal eosinophilia and angiogenesis in a mouse model of eosinophilic esophagitis, J Pediatr Gastroenterol Nutr, 53, 409, 10.1097/MPG.0b013e3182182ff8 · DOI
  129. Falahati, 2015, A recombinant antibody to Siglec-8 shows selective ADCC activity against mast cells from systemic mastocytosis patients, Blood, 126, 4092, 10.1182/blood.V126.23.4092.4092 · doi:10.1182/blood.v126.23.4092.4092
  130. Kiwamoto, 2012, Siglec-8 as a drugable target to treat eosinophil and mast cell-associated conditions, Pharmacol Ther, 135, 327, 10.1016/j.pharmthera.2012.06.005 · DOI · Paper page
  131. von Gunten, 2007, Intravenous immunoglobulin preparations contain anti-Siglec-8 autoantibodies, J Allergy Clin Immunol, 119, 1005, 10.1016/j.jaci.2007.01.023 · DOI
  132. Schaub, 2011, Dimeric IVIG contains natural anti-Siglec-9 autoantibodies and their anti-idiotypes, Allergy, 66, 1030, 10.1111/j.1398-9995.2011.02579.x · DOI
  133. Zhang, 2015, Siglec-10 is associated with survival and natural killer cell dysfunction in hepatocellular carcinoma, J Surg Res, 194, 107, 10.1016/j.jss.2014.09.035 · DOI
  134. Toubai, 2014, Siglec-G-CD24 axis controls the severity of graft-versus-host disease in mice, Blood, 123, 3512, 10.1182/blood-2013-12-545335 · DOI
  135. Wang, 2010, Alleviation of neurotoxicity by microglial human Siglec-11, J Neurosci, 30, 3482, 10.1523/JNEUROSCI.3940-09.2010 · DOI · Paper page
  136. Shahraz, 2015, Anti-inflammatory activity of low molecular weight polysialic acid on human macrophages, Sci Rep, 5, 16800, 10.1038/srep16800 · DOI
  137. McDonough, 2013, Pharmacogenomic association of nonsynonymous SNPs in SIGLEC12, A1BG, and the selectin region and cardiovascular outcomes, Hypertension, 62, 48, 10.1161/HYPERTENSIONAHA.111.00823 · DOI
  138. Kameda, 2015, Siglec-15 is a potential therapeutic target for postmenopausal osteoporosis, Bone, 71, 217, 10.1016/j.bone.2014.10.027 · DOI
  139. Stuible, 2014, Mechanism and function of monoclonal antibodies targeting Siglec-15 for therapeutic inhibition of osteoclastic bone resorption, J Biol Chem, 289, 6498, 10.1074/jbc.M113.494542 · DOI · Paper page
  140. Raetz, 2008, Children's Oncology Group Pilot Study. Chemoimmunotherapy reinduction with epratuzumab in children with acute lymphoblastic leukemia in marrow relapse: a Children's Oncology Group pilot study, J Clin Oncol, 26, 3756, 10.1200/JCO.2007.15.3528 · DOI · Paper page
  141. Kantarjian, 2016, Inotuzumab ozogamicin versus standard therapy for acute lymphoblastic leukemia, N Engl J Med, 375, 740, 10.1056/NEJMoa1509277 · DOI · Paper page
  142. Witzig, 2014, Anti-CD22 90Y-epratuzumab tetraxetan combined with anti-CD20 veltuzumab: a phase I study in patients with relapsed/refractory, aggressive non-Hodgkin lymphoma, Haematologica, 99, 1738, 10.3324/haematol.2014.112110 · DOI
  143. Wayne, 2017, Phase 1 study of the anti-CD22 immunotoxin moxetumomab pasudotox for childhood acute lymphoblastic leukemia, Blood, 130, 1620, 10.1182/blood-2017-02-749101 · DOI
  144. Wang, 2017, New development in CAR-T cell therapy, J Hematol Oncol, 10, 53, 10.1186/s13045-017-0423-1 · DOI · Paper page
  145. Petersdorf, 2013, A phase 3 study of gemtuzumab ozogamicin during induction and postconsolidation therapy in younger patients with acute myeloid leukemia, Blood, 121, 4854, 10.1182/blood-2013-01-466706 · DOI · Paper page
  146. Hills, 2014, Addition of gemtuzumab ozogamicin to induction chemotherapy in adult patients with acute myeloid leukaemia: a meta-analysis of individual patient data from randomised controlled trials, Lancet Oncol, 15, 986, 10.1016/S1470-2045(14)70281-5 · DOI · Paper page
  147. Raza, 2009, Complete remissions observed in acute myeloid leukemia following prolonged exposure to lintuzumab: a phase 1 trial, Leuk Lymphoma, 50, 1336, 10.1080/10428190903050013 · DOI
  148. Romain, 2014, Antibody Fc engineering improves frequency and promotes kinetic boosting of serial killingmediated by NK cells, Blood, 124, 3241, 10.1182/blood-2014-04-569061 · DOI · Paper page
  149. Rasmussen HS, Chang AT, Tomasevic N, Bebbington CA. Randomized, double-blind, placebo-controlled, ascending dose phase 1 study of AK002, a novel Siglec-8 selective monoclonal antibody, in healthy subjects. J Allergy Clin Immunol 141;2 Suppl.: AB403. · doi:10.1016/j.jaci.2017.12.950
  150. Beatson, 2016, The mucin MUC1 modulates the tumor immunological microenvironment through engagement of the lectin Siglec-9, Nat Immunol, 17, 1273, 10.1038/ni.3552 · DOI · Paper page
  151. Bénac, 2018, Preclinical development of first-in-class antibodies targeting Siglec-9 immune checkpoint for cancer immunotherapy [abstract], vol. 78
  152. Guangchao Cao, 2019, Normalization cancer immunotherapy: blocking siglec-15!, Signal Transduct Target Ther, 4, 10, 10.1038/s41392-019-0045-x · DOI
  153. Wang, 2019, Siglec-15 as an immune suppressor and potential target for normalization cancer immunotherapy, Nat Med, 25, 656, 10.1038/s41591-019-0374-x · DOI · Paper page
  154. Magorivska, 2016, Sialylation of anti-histone immunoglobulin G autoantibodies determines their capabilities to participate in the clearance of late apoptotic cells, Clin Exp Immunol, 184, 110, 10.1111/cei.12744 · DOI
  155. Chang, 2012, Leukocyte inflammatory responses provoked by Pneumococcal sialidase, MBio, 3, 10.1128/mBio.00220-11 · DOI · Paper page
  156. Chen, 2011, Amelioration of sepsis by inhibiting sialidase-mediated disruption of the CD24-Siglec G interaction, Nat Biotechn, 29, 428, 10.1038/nbt.1846 · DOI · Paper page
  157. Ohmi, 2016, Sialylation converts arthritogenic IgG into inhibitors of collagen-induced arthritis, Nat Commun, 7, 11205, 10.1038/ncomms11205 · DOI · Paper page
  158. Zhang, 2009, Coactivation of Syk kinase and MyD88 adaptor protein pathways by bacteria promotes regulatory properties of neutrophils, Immunity, 31, 761, 10.1016/j.immuni.2009.09.016 · DOI · Paper page
  159. Guzmán-Beltrán, 2013, Nordihydroguaiaretic acid attenuates the oxidative stress-induced decrease of CD33 expression in human monocytes, Oxid Med Cell Longev, 2013, 375893, 10.1155/2013/375893 · doi:10.1155/2013/375893
  160. Sakamoto, 2019, Glycan sulfation patterns define autophagy flux at axon tip via PTPRσ-cortactin axis, Nat Chem Biol, 15, 699, 10.1038/s41589-019-0274-x · DOI

Cited by

See all 57

Metadata

Authors
Lin, C.-H., Yeh, Y.-C., & Yang, K. D.
Venue
Journal of the Formosan Medical Association
Publisher
Elsevier BV
Published
2021-01
Volume
120
Issue
1
Pages
5-24
ISSN
0929-6646
Cited by
57
References
11
Language
en
Licence
Funders
Mackay Memorial Hospital (MMH-E−108-05)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.